Pfizer Tops Quarterly Estimates, Hikes Low End of Revenue Guidance on Strength of Non Covid Products Pfizer's latest quarterly results offer a sobering reminder that the world has moved on from Covid 19.
The company's decision to hike its low end revenue guidance and trim expectations for its Covid products is more than just a numbers game – it's a signal that the industry must adapt to new realities. Pfizer's $60.
5 billion to $62. 5 billion full year revenue forecast may seem reassuring, but it represents a decline from 2022 revenues of $62. 6 billion.